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Abstract:  Millions of women will be prescribed hormone
replacement therapy (HRT) and be told that it will
prevent osteoporosis occuring, despite the fact that there
is doubt about its long term usefulness.  Preventive
measures outlined in this article are much more preferable,
but need to be directed towards the whole population, not
just menopausal women.  The prevention of osteoporosis
is an important public health issue which needs to be
addressed now, not in the next century.  This article
explores the issues that surround the medicalisation of
post-menopausal osteoporosis.
Key Indexing Terms:  Osteoporosis, menopause,
medicalization, prevention.
INTRODUCTION
Osteoporosis is a term used to describe a reduction in
bone mass per unit volume.  It is caused by anything that
causes an increase in bone resorption compared with
bone formation (1).  Histologically, there is a decrease in
cortical bone thickness and a decrease in the number and
size of the trabeculae of cancellous bone (1).  It is the most
common metabolic bone disease and causes considerable
problems in the elderly (1).
In some patients osteoporosis is caused by diseases such
as hypogonadism, hyperthyroidism or partial gastrectomy
(2), but in most cases, no other disease is found.  One type
of osteoporosis occurs mainly in post-menopausal women
between 51 and 75 years of age and involves mainly loss
of trabecular bone (Type I), and another type involving
the loss of both cortical and trabecular bone occurs in men
and women older than 70 years of age (Type II).  In both
these types, fractures can occur, but in Type I the main
fractures are vertebral and forearm, and in Type II the
main fracture sites are femoral neck, pelvis, tibia and
humerus (1).
Osteoporosis is a public health problem in Australia and
other countries. In the USA in 1986, osteoporosis was
linked to 1.2 million fractures including 227,000 hip
fractures.  Of those with hip fractures, 12-20% die, 50%
of the survivors become nursing home candidates and
only 30-35% recover independence after the first year.
The cost of these fractures was estimated at over US$6
billion dollars in 1986 (2).
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Females have a greater risk of osteoporotic fracture than
males, with the age adjusted figures ranging from 6:1 at
the wrist and spine, to 2:1 at the hip (3).  Most post-
menopausal women lose bone at a rate between 7 - 13%
per decade (4).  Fracture rates increase exponentially
after menopause with over 80% of all fractures occurring
over the age of 75 years (5).  A 1986 study conducted in
New South Wales showed that age-specific hip fracture
rates doubled every 5.6 years for females over 50 years of
age.  The estimated number of hospital admissions will
increase by 83% by the year 2011 due to the ageing of the
Australian population (6).  In England it is estimated that
one in four women living to 90 years of age can expect a
hip fracture (5).
The natural process of “bone thinning” actually
commences long before menopause because a woman
achieves her “peak” bone density at about 30 years of age
(5,10).  Yet the message given to women in this country
is that most women will develop osteoporosis and that
Hormone Replacement Therapy (HRT) will prevent it,
and therefore that all women should take HRT and stop
this terrible problem from occurring.  Aging itself causes
bone “thinning” in both men and women but relatively
few will actually have osteoporosis severe enough to
cause fractures and pain (7).  Women commencing HRT
at 50 years of age or so will need to take it for more than
25 years to prevent the fractures that mainly occur over
the age of 75 and there is no indication that HRT is useful
over the age of 75 years anyway (8).
BONE DENSITY
The peak bone mass reached by women is influenced by
genetics to a large degree, but it can be influenced by the
woman’s calcium intake as well.  Calcium supplements
can increase bone mineral density by up to 3 to 4% in
growing pre-pubertal children, even if they take nearly
1000mg per day in their food (9).  If this gain persisted,
an increase in peak bone mass should be seen (9).
Calcium needs are greatest during adolescence and even
though bone is no longer growing in young adulthood,
young adults need more than 950mg of calcium per day
to remain in a positive calcium balance.  This positive
balance is needed to allow expansion of the periosteum
and for consolidation of the bone (10).
Normal premenopausal women not taking calcium
supplements (up to 1500 mg per day) will lose up to 1%
of bone per year (11,12).  The addition of calcium
supplementation prevents that loss.  Women who are
postmenopausal and who take calcium supplements of
1000mg per day may reduce their bone loss by up to 50%49
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at non-vertebral sites.  Further, perimenopausal women
who exercise and take calcium supplements lose less
bone than those who exercise only (11,12).
OTHER FACTORS ASSOCIATED WITH BONE
DENSITY
Weight bearing exercise can increase the bone density of
the lumbar spine and smoking can decrease the same
bone density by up to 10 percent (13).  Smoking can also
accelerate the loss of bone that occurs at menopause.  If
a woman stops smoking before the menopause, she can
reduce the risk of a hip fracture by about one quarter on
average, with heavy smokers reducing their risk even
further (5).
Many drugs, such as corticosteroids and some
anticonvulsants can decrease bone density, as can
excessive alcohol intake.  Excessive exercise inducing
amenorrhoea can lead to bone loss in young women
athletes and ovulatory dysfunction can cause a lower bone
mass to be achieved in adolescents and young adults (11).
Simply being thin can reduce bone density (5).  Anorexia
nervosa causes a rapid change in bone metabolism and
rheumatoid arthritis is associated with lower bone mass.
Moderate alcohol intake can be associated with a higher
bone density.  Women who have breast fed or who have
taken oral contraceptives have a higher bone mass at
menopause.  The advantage given by oral contraceptives
may not be long lasting however (14).
MENOPAUSE
In the early years of menopause there is a sudden increase
in the amount of bone lost, with most bone being lost in
the first 3 to 6 years.  Thereafter, bone loss attributed to
lack of oestrogen occurs for up to 20 years but interestingly,
only one third to one half of all bone lost is due to
menopause (11).  If oestrogen is commenced at menopause
the increased bone resorption is reduced, and this early
bone loss is prevented.
Once the oestrogen therapy is discontinued however, this
accelerated phase of bone loss occurs as at natural
menopause and any protection offered by oestrogen may
be lost 5 years after the oestrogens are stopped.  Even
women aged 75 or more who took oestrogen for more than
10 years had no major difference in bone density
measurements of their lumbar spine and femoral neck
compared with those women who had never taken
oestrogens (8).
EXERCISE
Post menopausal women who exercise three times a week
can reverse the normal bone loss and even women over 70
years of age can increase their bone density in this way
compared with sedentary women of the same age.  The
effect of this exercise can reduce the risk of hip fracture
by about half in both men and women (5).  One hour of
walking and range of motion exercises twice a week can
increase bone density by up to 3.5% in eight months (15).
Exercise and physical fitness also reduces the risk of falls.
Muscle strength is associated with increased effectiveness
of protective responses such as extending the arms, quick
stumbling movements of the feet and grabbing at nearby
objects.  These have the effect of absorbing the energy of
the fall with the hands or feet and reducing the force of
impact on the hip or spine.  A decrease in the amount of
soft tissue around the hip can cause there to be a decrease
in the ability of these tissues to absorb any impact.  In the
elderly there is a decrease in the muscle bulk and strength
which is age- related (16).
A reduction in physical activity over the past thirty years
has occurred in Britain, and increased mechanisation has
meant that jobs are less physically demanding than
before.  The effect of occupation on the bone density
appears to be permanent, and if the occupation is more
sedentary, the bone density is less (5).
In the same way, immobilization leads to a reduction in
bone density and muscle mass and an increased risk of hip
fracture.
VITAMIN D
There is a seasonal difference in bone density and in hip
fractures with bone density being lowest in winter and hip
fractures being highest in winter, which suggests that the
role of vitamin D may be important.  Fortified milk and
sunlight could be sources of vitamin D not utilized fully
(17).  Exposure to 30 minutes of sunlight per day, or an
increase in adult vitamin D intake by 4 fold could
influence bone density and decrease fracture risk without
increasing the risk of skin cancer or toxicity from vitamin
D (17).
OTHER FACTORS
Responses to falling may be affected by alcohol and
sedative drugs.  Hip fractures are increased in patients
who take long acting sedatives and who have a regular
intake of alcohol. “Drop attacks” and syncope also increase
the risk of falls and protective responses cannot be relied
upon during these (16).  Poor eyesight and coordination
also increases the risk of falls (18).  Neurological conditions
and lower limb disability are associated with abnormal
balance and increased numbers of falls (19).
Some patients who sustain vertebral crush fractures have
a normal vertebral bone mass, therefore vertebral bone
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elasticity may be an important factor.  The strength of
vertebral bodies decrease with age as an independent
factor (20).
TREATMENT OF OSTEOPOROSIS BY
HORMONE REPLACEMENT THERAPY
Postmenopausal lumbo vertebral bone loss can be changed
significantly to a bone gain by either continuous or
sequential oestrogen and progesterone therapy within
one year.  The changes in bone density can be seen as early
as 6 months after commencement of therapy, and after 12
months there can be as much as 5-6% improvement (20).
The benefit of hormone replacement therapy is seen for
as long as the woman maintains the treatment at least up
to 75 years of age.  Unfortunately, once the hormone
therapy is stopped, the protection also stops very quickly
(5).
Added bonuses suggested for women taking hormone
replacement therapy may be a reduction in ischaemic
heart disease of up to 45%, higher HDL cholesterol levels
and lower LDL levels, as well as lower glucose and
insulin levels.  These figures have been quoted generally
in healthy patients taking oestrogen alone (21), but the
combination of oestrogen and progestin may not adversely
affect this profile (22).  Many trials have been done with
women in a higher social class who have less mortality
from cardiovascular disease anyway (21).
Bone density screening has been advocated by some
people for all menopausal women, and the suggestion is
then to put all women with a bone density more than one
standard deviation below the mean onto oestrogen (11).
Unfortunately the difference in bone density at the neck
of the femur between the group of women with hip
fracture and the group of women without a fracture is only
half a standard deviation.  This implies that the difference
is too small for bone density testing to be a good screening
test for the whole population to predict which patients
will develop a hip fracture (5).  Any benefit in the
prevention of osteoporosis must be weighed against the
risk of developing breast cancer which has been shown to
be increased in women taking oestrogen alone or oestrogen
in combination with progestin.  This risk increases with
the length of time that the woman is taking hormone
replacement therapy, particularly with use for more than
five years, and also increases with the woman’s age,
especially over 55 years of age (23).
OTHER TREATMENTS AVAILABLE FOR
ESTABLISHED OSTEOPOROSIS
These include etidronate in a cyclical fashion two weeks
on, thirteen weeks off, which has been shown to increase
vertebral bone mineral content by about 5% and to
decrease the number of new vertebral fractures in
postmenopausal women with osteoporosis (24).  There
has been a recent interest in using calcitriol (1,25
dihydroxyvitamin D3) which increases calcium absorption
and stimulates osteoblasts (25).
HEALTH COSTS
Cost benefit analysis can be calculated by estimating
costs of drugs, consultations and tests required, as well as
the benefits.  If this is done for hormone replacement
therapy for women with menopausal symptoms, with
oestrogen alone or with both oestrogen and progesterone
(but not having any side effects from the progesterone),
it shows a benefit if hormone replacement therapy is used
for 15 years, reducing the risk of ischaemic heart disease
and osteoporotic fractures.  But for women who are
asymptomatic, prophylactic hormone replacement therapy
for prevention of osteoporotic fractures alone is not cost-
effective.  If cardiac benefit is included in these
asymptomatic women, only women on prolonged
oestrogen after hysterectomy are using health resources
reasonably (26).
ALTERNATIVES TO HORMONAL TREATMENT
OF MENOPAUSE RELATED OSTEOPOROSIS
1. Obtain the best peak bone mass possible.
2. Exercise programmes should be encouraged.  Regular
exercise could reduce hip fractures by up to 50% (5).
Exercise programmes for the elderly would require a
long term education campaign and a change in
personal and community attitudes towards exercise
by elderly people.
3. Calcium intake should be adequate throughout life.
There may be a role for vitamin D fortified milk as a
source for this calcium (17).
4. Everyone should be encouraged to stop smoking.
Women who stop smoking before menopause can
reduce their risk of fracture by about 25% (5)
5. Exercise should be outside if possible (17).
6. Avoidance of excess alcohol and sedatives should be
undertaken (16).
7. Prevention of falls at home should be a priority.
Many falls occur at home and reducing the likelihood
of falling on a hard surface can be done by carpeting
the areas. Grab bars could be installed and extra stair
rails would be helpful (19).  A simple night light may
help.
CONCLUSION
Post-menopausal osteoporosis has been medicalized.
Millions of women will be prescribed hormone
replacement therapy (HRT) and be told that it will
prevent osteoporosis occurring, despite the fact that there
is doubt about its long term usefulness.  Preventive
measures as outlined above are much more preferable,
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but need to be directed towards the whole population not
just menopausal women.  The prevention of osteoporosis
is an important public health issue which needs to be
addressed now, not in the next century.
REFERENCES
1. Wilson JD, Braunwald E, Isselbacher KJ, et al.  eds.
Harrison’s principles of internal medicine.  12th ed.
New York, McGraw-Hill.  Metabolic Bone disease.
1991: 1921-6.
2. Riggs BL, Melton LJ.  Involutional osteoporosis.  N
Eng J Med 1986; 314: 1676-86.
3. Cummings SR.  Are patients with hip fractures more
osteoporotic?  Review of the evidence.  Am J Med
1985; 78: 487-94.
4. Pocock NA, Eberl S, Eisman JA, et al.  Dual-photon
bone densitometry in normal Australian women: a
cross sectional study.  Med J Aust 1987; 146: 293-7.
5. Law MR, Wald NJ, Meade TW.  Strategies for
prevention of osteoporosis and hip fracture.  Br Med
J 1991; 303: 453-9.
6. Lord SR, Sinnett PF.  Femoral neck fractures:
admissions, bed use, outcomes amd projections.  Med
J Aust 1986; 145: 493-6.
7. Klein R.  The unethics of hormone replacement
therapy.  Bioethics News 1992; 11(3): 24-37.
8. Felson DT, Zhang Y, Hannan MT, et al.  The effect
of postmenopausal estrogen therapy on bone density
in elderly women.  N Eng J Med 1993; 329: 1141-6.
9. Johnston CC, Miller JZ, Slemenda CW, et al.  Calcium
supplementation and increases in bone mineral
density in children, N Eng J Med 1992; 327: 82-7.
10. Matkovic V.  Calcium intake and peak bone mass.  N
Eng J Med 1992; 327: 119-20
11. Riggs BL, Melton LJ.  The prevention and treatment
of osteoporosis.  N Eng J Med 1992; 327(9): 620-7.
12. Reid AR, Ames RW, Evans MC, et al.  Effect of
calcium supplementation on bone loss in
postmenopausal women.  N Eng J Med 1993; 328:
460-4.
13. Hopper JL, Seeman E.  The bone density of female
twins discordant for tobacco use.  NEJM 1994; 330:
387-92.
14. Hansen MA, Overgaard K, Riis BJ, et al.  Potential
risk factors for development of postmenopausal
osteoporosis - examined over a 12 year period.
Osteoporosis International 1991; 1: 95-102.
15. Chow M, Harrison JE, Notarius C.  Effect of two
randomized exercise programmes on bone mass in
healthy postmenopausal women.  Br Med J 1987;
295: 1441-4.
16. Cummings DR, Nevitt MC.  A hypothesis: the cause
of hip fractures.  J Gerontology: Medical sciences.
1989; 44: M107-11.
17. Khaw K, Sneyd M, Compston J.  Bone density
parathyroid hormone and 25-hydroxyvitamin D
concentrations in middle aged women.  Br Med J
1992; 305: 273-7.
18. Porter RW, Miller CG, Grainger D, et al.  Prediction
of hip fracture in elderly women: a prospective study.
Br Med J 1990; 301: 638-41.
19. Grisso JA, Kelsey JL, Strom BL, et al.  Risk factors
for falls as a cause of hip fracture in women. N Eng
J Med 1991; 324: 1326-31.
20 Munk-Jensen N, Neilsen SP, Obel EB. Eriksen PB.
Reversal of postmenopausal vertebral bone loss by
oestrogen and progesterone: a double blind placebo
controlled study.  Br Med J 1988; 296: 1150-2.
21 Posthuma WFM, Westendorp RGJ, Vandenbroucke
JP.  Cardioprotective effect of hormone replacement
therapy in postmenopausal women: is the evidence
biased?  Br Med J 1994; 308: 1268-9.
22. Nabulsi AA, Folsom AR, White A, et al.  Association
of hormone-replacement therapy with various
cardiovascular risk factors in postmenopausal women.
N Eng J Med 1993; 328: 1069-75.
23. Colditz GA, Hankinson SE, Hunter DJ, et al.  The use
of estrogens and progestins and the risk of breast
cancer in postmenopausal women.  N Eng J Med
1995; 332: 1589-93.
24. Storm T, Thamsborg G, Steiniche T, et al.  Effect of
intermittent cyclical etidronate therapy on bone mass
and fracture rate in women with postmenopausal
osteoporosis.  N Eng J Med 1990; 322: 1265-71.
25. Sambrook P.  Calcitriol and postmenopausal
osteoporosis.  Med J Aust 1992; 157: 364-5.
26. Cheung AP, Wren BG.  A Cost-effectiveness analysis
of hormone replacement therapy in the menopause.
Med J Aust 1992; 156: 312-6.
OSTEOPOROSIS AND MEDICALISATION
HOGG